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INTRODUCTION
Previous research on uric acid levels and pathology has fo-
cused mainly on the presence of hyperuricaemia as a risk
factor for cardiovascular disease (Kuwabara, 2016). The
topic of hypouricaemia has been much less studied and as a
result there is little awareness or understanding of any po-
tential risks of uric acid levels below the normal range.
With the advent of safer and more effective urate-lowering
medications, the potential for issues related to hypouricae-
mia has increased.
Recent studies (Pello et al., 2009; Fang et al., 2013; Perez-
Gomez, 2019) have found a possible association between
low serum uric acid levels and the development of neurode-
generative diseases. This raises the question whether nor-
malisation of uric acid concentration could prevent the de-
velopment of neurodegenerative diseases.
Uric acid and its function. Uric acid is an end product
from the degradation of the purine nucleosides, adenosine
and guanosine. In mammals, uricase breaks uric acid further
down to allantoin, which is then excreted in urine (Maiuolo
et al., 2016). Humans lack this enzyme, leaving uric acid as
the end product. Ames et al. (1981) hypothesised that uric
acid acts as an antioxidant by scavenging singlet oxygens
and radicals and they proposed that urate is as powerful as
ascorbate in its antioxidative function by reducing the oxi-
dative stress on erythrocytes. In 2008, Sautin and Johnson
published a research paper that agrees with the hypothesis
of Ames et al. (1981) about uric acid’s antioxidative func-
tion; however, they claimed that uric acid also has oxidative
effects that are pro-inflammatory. They observed that uric
acid in plasma acts as an antioxidant and within cells as a
pro-oxidant. They called this contradiction the oxidant-anti-
oxidant paradox (Sautin and Johnson, 2008). This paradox
states that hyperuricaemia can lead to an inflammatory re-
sponse causing gout, and endothelial dysfunction causing
cardiovascular diseases (Kanbay et al., 2013), while it can
act as a neuroprotector via the antioxidant capacity of uric
acid and subsequent reduction of oxidative damage. On
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Hypouricaemia has received relatively little attention in the literature. As a result, there is less
awareness or understanding of the potential risks of low uric acid levels. Emerging research indi-
cates that normal uric acid levels may have an antioxidative and neuroprotective effect. This
study aims to investigate possible associations between hypouricaemia and neurodegenerative
disease. Data was collected from seventy-seven outpatients and inpatients who underwent rou-
tine uric acid testing, who were then stratified into patients with and without neurodegenerative
disease. Patients with renal pathologies and patients using uric acid altering medications were ex-
cluded from the study. There was a significant difference in the prevalence of Alzheimer’s disease
between hypouricemic and normouricemic patients (p = 0.001), however there was no difference
in the prevalence of vascular dementia (p = 0.45). This study provides evidence that hypouricae-
mia has potential effects on health, specifically on the rate of neurodegenerative diseases such
as Alzheimer’s disease and gives weight to the potential neuroprotective role of uric acid.
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the other hand, low uric acid levels have been shown to de-
crease the activity of myeloperoxidase and increase lipid
peroxidation through the loss of the antioxidant properties
of uric acid (Becker et al., 2019). The reduced antioxidant
capacity is believed to be neurotoxic due to increased oxida-
tive damage (Fang et al., 2013), but it remains unclear if
this loss is sufficient to induce neurodegenerative diseases
(Settle, 2014).
Mortality and serum uric acid levels. It has been shown
that hyperuricaemia is an independent risk factor for hyper-
tension, but due to many confounders it has not been found
to be an independent risk factor for cardiovascular diseases
as of yet (Kuwabara, 2016). Another disease that is closely
related to hyperuricaemia is gout, which is managed mainly
by decreasing the serum uric acid levels. The current Euro-
pean guidelines recommend lowering uric acid to less than
6 mg/dl, but not less than 3 mg/dl (Richette et al., 2016).
For a long time there has been no established lower limit as
little research on the consequences of hypouricaemia has
been done, and it has only recently become a topic of inter-
est. There have been several studies that investigated the
mortality from high and from low uric acid levels. The
EPOCH-Japan study found that low uric acid levels are as-
sociated with a higher overall mortality rate from cardiovas-
cular diseases. They concluded that a J- or U-shaped asso-
ciation exists between low and high uric acid levels and
cardiovascular mortality (Zhang et al., 2016). Another study
conducted in Korea also confirmed a U-shaped, independ-
ent relationship between serum uric acid level and mortality
(Cho et al., 2016). The relationship between mortality and
hyperuricaemia can be explained by the activation of the
NLRP3 inflammasome and a resulting increase of Inter-
leukin-1ß and increased production of ROS (Braga et al.,
2017), which then trigger arteriosclerosis (Kuwabara,
2016). Conversely, causes of mortality associated with hy-
pouricaemia are not fully understood to date. The authors of
the Korean study gave possible explanations for the ob-
served mortality, such as malnutrition, side effects of medi-
cations that affect uric acid levels, other comorbidities, and
increased risk of oxidative stress due to a reduction in the
antioxidative properties of uric acid.
Causes of hypouricaemia. In the literature, hypouricaemia
is defined as a serum urate concentration less than 2 mg/dl
(Esparza and Garcia, 2016). It can be caused by decreased
uric acid production, seen in inherited disorders such as he-
reditary xanthinuria or purine nucleosidase phosphorylase
deficiency, or it can be secondary to urate lowering thera-
pies that are commonly used in the management of gout.
Further causes of hypouricaemia are either uric acid oxida-
tion with derivatives of uricase, which are commonly used
in oncology, and disorders that increase the urinary excre-
tion of urate, such as inherited familial renal hypouricaemia,
or acquired disorders such as Fanconi syndrome.
Inherited hypouricaemia. Cases of inherited low uric acid
levels in the absence of malnutrition and other diseases that
influence uric acid levels make an ideal model to investigate
the possible effects of hypouricaemia. These can serve as an
example of possible risks of clinical use of urate-lowering
therapies without an established ‘safe’ lower limit for blood
uric acid levels. Inherited defects that cause decreased uric
acid production are very rare. The most intensively studied
genetic cause for hypouricaemia is familial renal hypouri-
caemia, which results in increased excretion of uric acid.
The prevalence for renal hypouricaemia worldwide is un-
known, however cases have been reported in Japan (preva-
lence: 0.3%) (Nakayama et al., 2019) and South Korea
(prevalence: 1.39%) (Son et al., 2016). It is caused by loss
of function mutations in the renal tubular urate transporters.
With a mutation in the SLC22A12 gene (URAT1 trans-
porter) it is referred to as renal hypouricaemia type 1,
whereas with a mutation in SLC2A9 (GLUT9) as renal
hypouricaemia type 2. Most affected patients are asymp-
tomatic, although both types have been linked to nephro-
lithiasis and exercise-induced acute kidney injury (EIAKI).
Posterior reversible encephalopathy syndrome (PRES), a
more severe disorder that presents with headache, seizures
and other neurological findings, has been associated with
renal hypouricaemia type 2. It was suggested that PRES is
not due to severe hypouricaemia per se, but rather to an ad-
verse effect of severe EIAKI (Fujinaga et al., 2013). More
research is needed for further understanding on how renal
hypouricaemia can cause posterior reversible encephalo-
pathy syndrome. Overall, while cases of pathology related
to inherited hypouricaemia are well documented, most pa-
tients affected by hypouricaemia of a genetic origin appear
to be asymptomatic.
Acquired hypouricaemia. By far the most common cause
of acquired hypouricaemia is due to the use of urate-lower-
ing therapies and subsequent decreased uric acid production
(Mount, 2018). In most guidelines the recommendation is to
lower plasma urate below 6 mg/dl. If tophi are present, the
guidelines suggest to further lower plasma urate below 5
mg/dl (Sautner et al., 2013; Graf et al., 2015; Richette et
al., 2016; Hui et al., 2017; Kiltz et al, 2017; Yu, 2018).
There are only two guidelines, the British Society for
Rheumatology and EULAR recommendation (2017), men-
tioning potential outcomes from lower urate levels. It is be-
lieved that low urate levels increase the risk for neuro-
degenerative disorders (Bowman et al., 2010), such as
Parkinson’s disease, Alzheimer’s disease and Amyotrophic
lateral sclerosis, and that elevated levels may have a protec-
tive function (Fang et al., 2013; Paganoni and Schwarz-
schild, 2016). Furthermore, in the past decade the results of
seven randomised clinical trials have been published that in-
vestigated potential dangers of urate-lowering therapy by
the three most commonly used therapies (Xanthine oxidase
inhibitors, recombinant uricase and uricosuric agents)
(Becker et al., 2005; Sundy et al., 2011; Saag et al., 2016;
Bardin et al., 2017; Dalbeth et al., 2017; Tausche et al.,
2017; White et al., 2018). In the largest trial, the CARES
study, a statistical significant relationship between intensive
urate lowering therapy and mortality was found (White et
al., 2018). In the other trials, this relationship was not statis-
tical significant, but mortality was highest in the arms with
the greatest urate lowering effect, raising the suspicion of
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safety concerns about commonly used gout medication
without a lower cut-off threshold (Perez-Gomez et al.,
2019). To date only EULAR recommendations suggest a
specific threshold, in this case not lower than 3 mg/dl. Other
than EULAR and the British Society for Rheumatology
guidelines (Richette et al., 2016; Hui et al., 2017) major
published guidelines currently address the potential dangers
of lowering urate levels beyond the normal range.
Adverse effects of hypouricaemia. There is still little de-
finitive knowledge about the specific short- and long-term
clinical effects of hypouricaemia. One potential danger that
can occur from urate-lowering therapy with xanthine oxi-
dase inhibitors is the accumulation of hypoxanthine and
xanthine, which that could eventually cause xanthine neph-
ropathy. This remains a theoretical concern as no cases (ex-
cept for patients with tumor lysis syndrome) have been re-
ported to date (Bellomo and Selvi, 2018). It is thought that
uric acid has a protective antioxidant function and that loss
of this antioxidative function can occur in cases of hypouri-
caemia. It is less clear if the loss of antioxidative protection
due to subnormal uric acid levels is sufficient to induce neu-
rodegenerative disease.
This aim of the study was to investigate the possible associ-
ations between hypouricemia and neurodegenerative dis-
ease.
MATERIALS AND METHODS
Study subjects. The data was collected from patients
treated in Daugavpils Regional Hospital, Orto Clinic, Rîga
East Clinical University Hospital, and Pauls Stradiòð Clini-
cal University Hospital, on an outpatient or inpatient basis
after consent was obtained, and consisted of a randomised
cross section of patients whose serum uric acid concentra-
tion had been measured as part of their routine blood tests.
These patients were not admitted for uric acid related pa-
thology and did not display acute symptoms related to
blood uric acid levels. Additionally, none of the studied pa-
tients were receiving treatment for their uric acid levels. Pa-
tients with high creatinine levels or chronic kidney diseases
were excluded from data analysis due to secondarily ele-
vated uric acid levels. Patients who did not agree to the use
of their data for research purposes were also excluded from
analysis. Data about patient age, height, weight and present
and past medical history, with specific interest to neurode-
generative diseases, as well as laboratory data such as uric
acid concentration and serum creatinine levels were also
collected from the patient files. Patients with neurodegen-
erative diseases were diagnosed by certified psychiatrists
according to the current guidelines prior to the start of this
study. For the analysis, patients were then stratified into pa-
tients with neurodegenerative disease and patients without
neurodegenerative disease.
Variables. In this study, hypouricaemia was defined as less
than 200 µmol/l and only one measurement was taken. Cre-
atinine levels higher than 110 µmol/l were excluded from
the study. Neurodegenerative diseases of interest included
Alzheimer’s disease and vascular dementia. Alzheimer’s
disease was defined as G30 in the ICD-10 classification and
vascular dementia was defined as F01.5 in the ICD-10 clas-
sification.
Statistical analysis. Statistical analyses were performed us-
ing SPSS Statistics software (Statistical Package for the So-
cial Sciences, SPSS Inc, Chicago, IL), Version 20, 2018.
Demographic data were expressed as mean with standard
deviations. The statistical analysis was performed in accor-
dance with objectives using following statistical methods:
Kolmogorov–Smirnov test, Pearson correlation coefficient,
two tailed t-test for independent means, Fisher exact proba-
bility test and chi-squared test. Statistical significance was
set at  = 0.05.
RESULTS
Study subjects’ characteristics. Of the 100 interviewed
patients, 18 were excluded due to high creatinine levels and
five patients refused to be included in the research. As a re-
sult, 77 patients were included in the study. The group of
patients with neurodegenerative disease included 45 pa-
tients and the mean age the group of patients without a neu-
rodegenerative disease was 32 patients. The demographic
statistics of the study population are given in Table 1.
Uric acid correlation with age and kidney function. Uric
acid is excreted from the body by the kidney, the function
of which decreases with age (Weinstein and Anderson,
2010). Therefore, the correlation between serum uric acid
concentration and GFR was calculated. As expected, there
was a moderate positive correlation (r = 0.58) for patients
for neurodegenerative disease and for patients without
neurodegenerative diseases (r = 0.51). Both results were sta-
tistically significant at p < 0.05. Additionally, the correla-
tion between serum uric acid concentration and patient age
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Age in years 81 ± 10 70 ± 13
Weight in kg 75.6 ± 11.0 80.3 ± 14.0
Height in cm 170 ± 7 167 ± 9
BMI 26.3 ± 11.0 28.8 ± 13.0
Uric acid in µmol/l 387 ± 210 409 ± 156
Creatinine in µmol/l 83 ± 26 76 ± 20
GFR in ml/min/1.73 m² 98 ± 16 96 ± 14
Alzheimer's disease patients 4 NA
Vascular dementia patients 40 NA
Dementia in other diseases
classified elsewhere
1 NA
was tested by Pearson correlation coefficient. The results
showed that in both groups there was no correlation (r =
0.0615) for patients with neurodegenerative diseases and
modest correlation (r = –0.70) for patients without neuro-
degenerative disease and the latter one lacked statistical sig-
nificance at p < 0.05.
Uric acid level and its association with neurodegenera-
tive diseases in stratified age groups. The groups of pa-
tients with a neurodegenerative disease and without neuro-
degenerative disease were stratified into age groups of
50–79 years and 80 years to test the effect of age on vascu-
lar dementia. The mean uric acid levels for the different age
groups are shown in Figure 1. The stratified groups were
tested with a Fisher exact probability test to determine sig-
nificance of relationships between the two age groups and
the diagnosis of vascular dementia at a significance level
p < 0.05. The stratified groups did not show statistically sig-
nificant relationships between age groups and Alzheimer’s
disease.
Hypouricaemia and its association with neurodegenera-
tive diseases. As a final step the patients with hypouricemic
levels were compared to patients with normal uric acid lev-
els for frequency of occurrence of vascular dementia and
Alzheimer’s disease. This was done with a chi-squared test
of independence with a significance level p < 0.05. The re-
sult for a non-random association between the rate of vascu-
lar dementia in patients with hypouricaemia and patients
with normal serum uric acid levels was not significant 2
(1, n = 77) = 0.56, p = 0.45, indicating no significant differ-
ence in the frequency of occurrence of vascular dementia
depending on uric acid levels. However, for patients with
Alzheimer’s disease, the chi-square analysis for the rate of
Alzheimer’s disease in patients with hypouricaemia and pa-
tients with normal blood uric acid levels showed a
non-random distribution. This indicates a statistically sig-
nificant difference in the rate of this disease among hypo-
and normouricemic patients, significant at 2 (1, n = 77) =
10.5, p = 0.001.
DISCUSSION
In this study, the possible relationship between serum uric
acid and neurodegenerative diseases was explored, to pro-
vide addition information on the suggested link between
low uric acid levels and loss of reduction in antioxidant ca-
pacity leading to the increased occurrence of neurodegen-
erative diseases.
The reasoning behind this suspected relationship is the com-
plex role of uric acid in the body. It can induce inflamma-
tion, endothelial dysfunction and oxidative stress, but it is
also known to be a powerful antioxidant. This is known as
the oxidant-antioxidant paradox (Sautin and Johnson,
2008). Laboratory studies have shown that the loss of uric
acid causes a reduction in antioxidant capacity. This is me-
diated by decreased myeloperoxidase activity and increased
lipid peroxidation and subsequent oxidative damage. Multi-
ple studies have linked these processes to neurodegenerative
diseases such as Parkinson’s disease, multiple sclerosis and
Alzheimer’s disease. However, this relationship was not
shown for vascular dementia (Squadrito et al, 2000; Matt-
son, 2003; Singh, 2019). This does not come as a surprise if
one takes the pathogenesis and risk factors for these dis-
eases into account.
Alzheimer’s disease is characterised primarily by the accu-
mulation of neurotoxic metabolic products and abnormal
proteins such a beta amyloid and neurofibrillary tangles
(Longo and Massa, 2004; Kocahan and Doan, 2017). This
creates an environment hostile to normal brain cell function
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Fig. 1. Average uric acid
levels after stratification of
patients into age groups
and results in progressive dysregulation and synaptic dys-
function. Several studies have implicated neuronal excito-
toxicity from overstimulation of N-methyl-D-aspartate
(NMDA) receptors (Olivares et al., 2012). These specific
neurotoxic processes may be counteracted by neuro-
protective factors in the brain, with the antioxidative effects
of normal blood uric acid playing a significant role.
On the other hand, vascular dementia has shown a contra-
dictory result in recent studies and does not seem to be asso-
ciated with lower uric acid levels. This makes sense in light
of the abundance of risk factors and multiple etiologies of
vascular dementia. While individual neuroprotective factors
may certainly play a role in the onset or extent of vascular
dementia, the relative weight of such neuroprotective fac-
tors may be outweighed by the larger contributions of car-
diovascular, renal, and general endothelial risk factors. With
this in mind, the relationships between age and Alzheimer’s
disease and age and vascular dementia were explored. As
expected, there was no such statistical significant relation-
ship for Alzheimer’s disease. However, the relationship be-
tween age and vascular dementia was statistical significant,
indicating higher prevalence of vascular dementia with in-
creased age.
The results of our study are further in line with other stud-
ies. The mean serum uric acid levels were compared be-
tween patients with and without neurodegenerative disease.
A meta-analysis on effects of low uric acid levels found no
significant difference in serum uric acid levels between pa-
tients suffering from Alzheimer’s’ disease and healthy indi-
viduals, but there was a trend towards lower uric acid levels
among patients with Alzheimer’s disease (Chen et al.
2014). This trend was also confirmed in our study, with no
significant difference between the two groups, but lower
values were noted in the group with neurodegenerative dis-
eases. This led us to further analyse the group of patients
with neurodegenerative diseases. Patients with hypourice-
mic levels were compared to patients with normal uric acid
levels for the occurrence of vascular dementia and Alz-
heimer’s disease. In other studies (Squadrito et al, 2000;
Mattson, 2003; Singh, 2019), we found a statistical signifi-
cant relationship between hypouricaemia and Alzheimer’s
disease, but not for vascular dementia.
These findings are especially important, as through the ad-
vent of safer and more effective urate lowering medications,
the risk of a patient becoming hypouricemic increases.
There are only two guidelines, the British Society for Rheu-
matology and EULAR recommendation (2017), that men-
tion potential outcomes from lowering urate levels, and
only the EULAR recommendation has defined a lower
threshold plasma urate level with a recommended range be-
tween 3 mg/dl to 6 mg/dl. This range seems appropriate tak-
ing into account that we defined hypouricaemia as serum
uric acid levels below 200 µmol/l (3.36 mg/dl). With more
research on the link between hypouricaemia and neurode-
generative disease evolving, the range suggested by EU-
LAR should be revisited and re-evaluate the optimal range
that protects patients from losing the neuroprotection that
uric acid offers.
There are three main limitations of this study. The first limi-
tation was the sample size, which while large enough to de-
termine statistical significance in the most important tests,
could have benefited from further enlargement to ensure de-
tection of all statistically significant associations. Secondly,
serum uric acid levels were measured only once. Therefore,
transient changes in hypo- or hyperuricemic status cannot
be excluded. While patients placed on uric acid lowering
medications and patients with renal insufficiency were ex-
cluded from the study, and therefore it is unlikely that over-
all uric acid status would change significantly, it is possible
that serial measurements of uric acid levels would more
confidently sort patients into appropriate hypo- and hyperu-
ricemic categories. And lastly, the majority of test subjects
were drawn from hospitalised patients admitted for some
medical pathology. As in many studies dealing with a hos-
pitalised patient population, there is a possibility that results
may vary between the patient populations.
CONCLUSION
This study provides evidence that hypouricaemia has poten-
tial effects on health, specifically on the rate of neurodegen-
erative diseases such as Alzheimer’s disease. The lack of a
statistically significant association for vascular dementia
lends additional evidence to the potential role of uric acid as
a factor in diseases mediated by specific neurodegenerative
processes, as opposed to a general neuroprotective effect.
While no research to date has found convincing evidence
for a particular lower bound of normal blood uric acid lev-
els, this research furthers the argument that one is needed.
In the absence of specific evidence-based recommendations,
the EULAR guidelines of maintaining blood uric acid levels
between 3 mg/dl to 6 mg/dl seem prudent. Future research
should focus on identifying other pathological associations
with low uric acid levels and also on determining a definite
lower bound of normal serum uric levels.
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HIPOURIKÇMIJAS NOZÎME NEIRODEÌENERATÎVO SLIMÎBU ATTÎSTÎBÂ
Hipourikçmijai literatûrâ ticis pievçrsts salîdzinoði maz uzmanîbas. Tâ rezultâtâ ir mazâka izpratne un zinâðanas par zemâ urînskâbes lîmeòa
iespçjamo ietekmi uz veselîbu. Jaunâkie pçtîjumi râda, ka normâlam urînskâbes lîmenim varçtu bût antioksidantîvs un neiroprotektîvs
efekts. Ðî pçtîjuma mçríis ir izpçtît iespçjamâs saistîbas starp hipourikçmiju un neirodeìeneratîvâm slimîbâm. Dati tika savâkti no
septiòdesmit septiòiem ambulatorajiem un stacionârajiem pacientiem, kuriem regulâri tika veiktas urînskâbes pârbaudes. Pacienti tika
sadalîti divâs grupâs: pacienti ar neirodeìeneratîvâm slimîbâm un pacientiem bez neirodeìeneratîvâm slimîbâm. Pacienti ar nieru
patoloìijâm vai pacienti, kuri lieto urînskâbi ietekmçjoðos medikamentus, tika izslçgti no pçtîjuma. Pacientiem ar hipourikçmiju
Alcheimera slimîba tika novçrota ievçrojami bieþâk, salîdzinâjumâ ar tiem pacientiem, kuriem urînskâbe bija normâlâ lîmenî (p = 0,001).
Turpretî saslimðanas bieþums ar vaskulâro demenci nebija atkarîgs no urînskâbes lîmeòa asinîs (p = 0,45). Pçtîjums pierâda, ka
hipourikçmijai varçtu bût ietekme uz cilvçka veselîbas stâvokli, îpaði uz neirodeìeneratîvo slimîbu izcelðanâs bieþumu, kâ piemçram
Alcheimera slimîbu, un norâda uz urînskâbes iespçjamo neiroprotektîvo lomu.
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